Information Provided By:
Fly News Breaks for December 19, 2019
Dec 19, 2019 | 07:48 EDT
As previously reported, Jefferies analyst Biren Amin downgraded Synthorx (THOR) to Hold from Buy with a price target of $68, up from $23, citing the company's announcement of a deal to be acquired by Sanofi (SNY) for $68 per share in cash. The deal makes it clear that Sanofi believes that IL-2 will "be a backbone of IO therapy as well as will be used in combination with other IO therapies," said Amin, who does not expect any additional bidders for Synthorx.